Phase III trial of BIVV-009 for cold agglutinin disease

Trial Profile

Phase III trial of BIVV-009 for cold agglutinin disease

Planning
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs TNT 009 (Primary)
  • Indications Autoimmune haemolytic anaemia
  • Focus Therapeutic Use
  • Sponsors Bioverativ
  • Most Recent Events

    • 01 Nov 2017 According to a Bioverativ media release, the company plans to initiate this trial by the end of the year 2017.
    • 30 Oct 2017 New trial record
    • 26 Oct 2017 According to a Bioverative media release, the company expected to initiate this trial before the end of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top